Objective: To evaluate the economic efficiency of rivastigmine capsule versus rivastigmine transdermal patch in the treatment of Alzheimer's disease (AD) from the perspective of Chinese medical and health system. Methods: Markov model was constructed to simulate the lifetime quality adjusted life years (QALYs) and incremental cost-utility ratio (ICUR)，and one-way sensitivity analysis and probability sensitivity analysis were conducted to further test the correctness and stability of the model results. Results: The results of basic analysis showed that patients in the transdermal patch group gained 1.10 QALYs more than those in the capsule group while spending 79758.79 yuan less，with an ICUR of -72，507.99 yuan/QALY，which was the absolute advantage scheme. The one-way sensitivity analysis showed that these three most sensitive factors to the model were the cost per cycle of capsules，the discount rate and the utility value of the severe state. The probability sensitivity analysis showed that transdermal patch group consistently had a cost-effectiveness advantage regardless of the willingness to pay value. Conclusion: Compared with rivastigmine capsule，rivastigmine transdermal patch has lower cost and higher utility，which is a more economical and advantageous scheme.